Nuclear Imaging of CNS Diseases in Rodent Models
Supported by:
31 May 2016
ABOUT THIS WEBINAR
Nuclear imaging provides translational and noninvasive in vivo methodology to reliably quantify pathological changes during disease progression and allows evaluation of therapeutic effects of existing or novel drugs against the disease. This webinar showcases new developments of CNS Discovery Services at Charles River, including new access to a nearby cyclotron particle accelerator that can be used to produce short-lived positron-emitting isotopes suitable for PET imaging. In addition, we will discuss arterial input function (AIF) generation from rodents as a gold standard analysis methodology in PET imaging.
We will highlight how these new capabilities, combined with our expertise with PET and SPECT imaging and associated ex vivo techniques, provide a comprehensive state-of-the-art toolkit for evaluating pathophysiology and drug effects in animal models of CNS disorders.
PRESENTERS
- Tuulia Huhtala, PhD, Lead Scientist, Charles River Discovery, Finland
- Jussi Rytkönen, PhD, Research Associate, Charles River Discovery, Finland
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Imaging
Related organisations
Charles River Laboratories